Pharmaceuticals

Projected Growth of the Global High Throughput Screening (HTS) Market to Reach $2.25 Billion by 2029

December 3, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the high throughput screening (hts) market from 2025–2034 with trusted insights from The Business Research Company

What CAGR And Valuation Are Anticipated For The High Throughput Screening (HTS) Market By The End Of 2029?

The market for peptide and anticoagulant drugs has experienced robust expansion in recent years. This market is projected to expand from $1.41 billion in 2024 to $1.54 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 9.6%. Historically, this growth has been driven by factors such as a rise in healthcare spending, greater investments in healthcare, increasing market liberalization, an uptick in the global count of infected patients, and a higher prevalence of genetic conditions.

The peptide and anticoagulant drugs market is projected to experience robust growth in the coming years. This market is forecast to reach $2.25 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 9.9%. The expansion during the forecast period is primarily driven by the increasing prevalence of chronic diseases, an aging population, the rising incidence of cancer, the ongoing expansion of emerging markets, and the escalating burden of cardiovascular diseases. Key trends anticipated in this period include significant advancements in biotechnology, continuous technological developments in drug delivery, improvements in diagnostic techniques, further advancements in pharmacology, and the introduction of new anticoagulant products.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21252&type=smp

Which Business Drivers Are Underpinning The Growth Of The High Throughput Screening (HTS) Market?

The increasing occurrence of chronic illnesses is anticipated to drive the expansion of the peptide and anticoagulant drugs market in the future. These long-term health conditions are characterized by their extended duration, often lasting for years or a lifetime. This rise in chronic disease prevalence stems from factors like an aging demographic, unhealthy lifestyle choices, and a greater incidence of risk factors such as obesity, high blood pressure, and diabetes. Peptide and anticoagulant medications play a crucial role in managing chronic conditions such as cardiovascular diseases, thrombosis, and stroke by preventing blood clots and specifically targeting disease pathways, thereby enhancing patient outcomes. For example, data released by the US government organization, Centers for Disease Control and Prevention, in May 2023, indicated that fatalities from heart disease and cancer reached 695,547 in 2022, marking an increase from 605,213 recorded in 2021. Consequently, the growing prevalence of chronic diseases is a significant impetus behind the growth of the peptide and anticoagulant drugs market.

What Are The Principal Segment Types In The High Throughput Screening (HTS) Market?

The peptide and anticoagulant drugs market covered in this report is segmented –

1) By Type: Hormonal, Antibiotic, Ace Inhibitor, Antifungal, Other Types

2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

4) By Application: Infectious Diseases, Gynecology, Cancer, Diabetes, Cardiology, Osteoporosis, Other Applications

5) By End-users: Hospitals, Specialty Clinics, Homecare, Other End-users

Subsegments:

1) By Hormonal: Peptide Hormones, Steroid Hormones, Thyroid Hormones, Other Hormones

2) By Antibiotic: Beta-Lactams, Macrolides, Tetracyclines, Fluoroquinolones, Other Antibiotics

3) By ACE Inhibitor: Captopril, Enalapril, Lisinopril, Ramipril, Other ACE Inhibitors

4) By Antifungal: Azoles, Echinocandins, Polyenes, Allylamines, Other Antifungals

5) By Other Types: Immunosuppressants, Antineoplastic Agents, Cardiovascular Drugs, Other Peptide And Anticoagulant Drugs

How Are Industry Trends Steering The Expansion Of The High Throughput Screening (HTS) Market?

Leading companies in the peptide and anticoagulant drugs market are concentrating on advancements in anticoagulant therapies, such as oral anticoagulants, with the goal of enhancing efficacy, improving patient compliance, and diminishing the risk of bleeding complications. An oral anticoagulant is a medication consumed orally to prevent blood clots by inhibiting clotting factors within the blood. For instance, in April 2024, Cadrenal Therapeutics Inc., a US-based pharmaceutical company, obtained Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for tecarfarin, its late-stage oral anticoagulant. Tecarfarin is designed as a novel, reversible blood thinner aimed at lowering the risk of heart attacks, strokes, and mortality related to blood clots in patients with rare cardiovascular conditions. The ODD specifically applies to preventing thromboembolism and thrombosis in patients with implanted mechanical circulatory support devices, including left ventricular assist devices (LVADs), right ventricular assist devices (RVADs), ventricular assist devices (VADs), biventricular assist devices, and total artificial hearts.

Which Companies Are Contributing Significantly To The High Throughput Screening (HTS) Market Growth?

Major companies operating in the peptide and anticoagulant drugs market are Pfizer Inc., Merck & Co. Inc., Bayer AG, F. Hoffmann-La Roche Ltd, Sanofi S.A., Abbott Laboratories, Novartis AG, Novo Nordisk A/S, Viatris Inc., Baxter International Inc., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Bachem Holding AG, Bharat Serums and Vaccines Limited, Wockhardt Limited, AmbioPharm Inc., MITS Healthcare Private Limited, Siddha Pharmacy, Circle Pharma Inc., Tenwel Pharmaceuticals Pvt. Ltd.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/peptide-and-anticoagulant-drugs-global-market-report

Which Region Offers The Most Opportunity For High Throughput Screening (HTS) Market Expansion?

North America was the largest region in the peptide and anticoagulant drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and anticoagulant drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=21252&type=smp

Browse Through More Reports Similar to the Global High Throughput Screening (HTS) Market 2025, By The Business Research Company

Anticoagulant Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anticoagulant-global-market-report

Biosimilar Therapeutic Peptide Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biosimilar-therapeutic-peptide-global-market-report

Peptide Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795